Skip to main content
SpringerLink
Log in

Somatostatin and thyroid

  • Opinion
  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. degli Uberti EC, Hanau S, Rossi R, et al. Somatostatin reduces 3H-thymidine incorporation and c-myc, but not thyroglobulin ribonucleic acid levels in human thyroid follicular cells in vitro. J Clin Endocrinol Metab 1991, 72: 1364–71.

    Article  PubMed  Google Scholar 

  2. Davies RR, Miller M, Turner SJ, et al. Effects of somatostatin analogue SMS 201 — 995 in normal man. Clin Endocrinol (Oxf) 1986, 24: 665–74.

    Article  CAS  Google Scholar 

  3. Vitale G, Caraglia M, Ciccarelli A, et al. Current approaches and perspectives in the therapy of medullary thyroid carcinoma. Cancer 2001, 91: 1797–808.

    Article  PubMed  CAS  Google Scholar 

  4. Ain KB, Taylor KD. Somatostatin analogs affect proliferation of human thyroid carcinoma cell lines in vitro. J Clin Endocrinol Metab 1994, 78: 1097–102.

    PubMed  CAS  Google Scholar 

  5. Forssell-Aronsson EB, Nilsson O, Bejegard SA, et al. 111In-DTPA-D-Phe1-octreotide binding and somatostatin receptor subtypes in thyroid tumors. J Nucl Med 2000, 41: 636–42.

    PubMed  CAS  Google Scholar 

  6. Papotti M, Kumar U, Volante M, Pecchioni C, Patel YC. Immunohistochemical detection of somatostatin receptor types 1–5 in medullary thyroid carcinoma of the thyroid. Clin Endocrinol (Oxf) 2001, 54: 641–9.

    Article  CAS  Google Scholar 

  7. Kurtaran A, Scheuba C, Kaserer K, et al. Indium-111-DTPA-D-Phe-1-Octreotide and Technetium-99m-(V)-dimercaptosuccinic acid scanning in the preoperative staging of medullary thyroid carcinoma. J Nucl Med 1998, 36: 1907–9.

    Google Scholar 

  8. Gorges R, Kahaly G, Muller-Brand J, Macke H, Roser HW, Bockisch A. Radionuclide-labeled somatostatin analogues for diagnostic and therapeutic purposes in nonmedullary thyroid cancer. Thyroid 2001, 11: 647–59.

    Article  PubMed  CAS  Google Scholar 

  9. Robbins RJ, Hill RH, Wang W, Macapinlac HH, Larson SM. Inhibition of metabolic activity in papillary thyroid carcinoma by a somatostatin analogue. Thyroid 2000, 10: 177–83.

    Article  PubMed  CAS  Google Scholar 

  10. Krenning EP, de Jong M, Kooij PP, et al. Radiolabelled somatostatin analogue(s) for peptide receptor scintigraphy and radionuclide therapy. Ann Oncol 1999, 10: S23–9.

    Article  PubMed  Google Scholar 

  11. Diez JJ, Iglesias P. Somatostatin analogs in the treatment of medullary thyroid carcinoma. J Endocrinol Invest 2002, 25: 773–8.

    Article  PubMed  CAS  Google Scholar 

  12. Zatelli MC, Tagliati F, Taylor JE, Rossi R, Culler MD, degli Uberti EC. Somatostatin receptor subtypes 2 and 5 differentially affect proliferation in vitro of the human medullary thyroid carcinoma cell line TT. J Clin Endocrinol Metab 2001, 86: 2161–9.

    PubMed  CAS  Google Scholar 

  13. Zatelli MC, Tagliati F, Taylor JE, Piccin D, Culler MD, degli Uberti EC. Somatostatin, but not somatostatin receptor sub-types 2 and 5 selective agonists, inhibits calcitonin secretion and gene expression in the human medullary thyroid carcinoma cell line, TT. Horm Metab Res 2002, 34: 229–33.

    Article  PubMed  CAS  Google Scholar 

  14. Zatelli MC, Tagliati F, Piccin D, et al. Somatostatin receptor subtype 1-selective activation reduces cell growth and calcitonin secretion in a human medullary thyroid carcinoma cell line. Biochem Biophys Res Commun 2002, 297: 828–34.

    Article  PubMed  CAS  Google Scholar 

  15. Bruns C, Lewis I, Briner U, Meno-Tetang G, Weckbecker G. SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol 2002, 146: 707–16.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Section of Endocrinology, Department of Biomedical Sciences and Advanced Therapies, University of Ferrara, Via Savonarola 9, 44100, Ferrara, Italy

    M. C. Zatelli & E. C. degli Uberti MD

  2. Institute of Endocrinology, University of Milan, Milan, Italy

    E. Roti

Authors
  1. M. C. Zatelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. E. Roti
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. E. C. degli Uberti MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to E. C. degli Uberti MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Zatelli, M.C., Roti, E. & degli Uberti, E.C. Somatostatin and thyroid. J Endocrinol Invest 26, 765–766 (2003). https://doi.org/10.1007/BF03347362

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03347362

Key-words

Search

Navigation